CT-based radiomics scores predict response to neoadjuvant chemotherapy and survival in patients with gastric cancer

June 4, 2020 | Radiomics

A study published in BMC Cancer in 2020 reported that a team from the First Affiliated Hospital of Sun Yat-sen University in China has constructed and validated an effective CT radiomics score…that was effective in predicting treatment response to neoadjuvant chemotherapy and in stratifying patients with gastric cancer into different survival groups. The study identified 25 radiomic features associated with treatment response to neoadjuvant chemotherapy for gastric cancer. These were histogram parameters, GLCM, and GLRLM with more than half of the features being GLRLM. GLCM and GLRLM were important markers of intra-tumour homogeneity. These values were higher in patients with no response to neoadjuvant chemotherapy, which indicated that the intratumoral heterogeneity was more apparent in these patients than in the responding patients.

Many studies have reported that tumours with greater intratumoral heterogeneity tended to be more aggressive in terms of proliferation, metastasis, and angiogenesis and thus might be more resistant to neoadjuvant chemotherapy.


Read the full article here>>